19:08 , Apr 20, 2018 |  BC Week In Review  |  Company News

Advent to acquire Sanofi's EU generics business

VC firm Advent International Corp. (Boston, Mass.) said it will acquire from Sanofi (Euronext:SAN; NYSE:SNY) the pharma's European generics business, Zentiva Group A/S, for €1.9 billion ($2.3 billion). Last year, Sanofi indicated it was looking...
19:24 , Apr 17, 2018 |  BC Extra  |  Company News

Advent to acquire Sanofi's European generics unit for €1.9B

VC firm Advent International Corp. (Boston, Mass.) said it will acquire from Sanofi (Euronext:SAN; NYSE:SNY) the pharma's European generics business, Zentiva Group A/S, for €1.9 billion ($2.3 billion). Last year, Sanofi indicated it was looking...
20:02 , Apr 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) Cell culture and mouse studies suggest inhibiting MLLT1 could help treat AML. In multiple AML cell lines, MLLT1 knockout decreased growth compared with normal MLLT1 expression. In two xenograft mouse...
20:09 , Mar 10, 2017 |  BC Week In Review  |  Clinical News

Voclosporin: Additional Ph IIb AURA-LV data

Additional data from the double-blind, international Phase IIb AURA-LV trial in 265 patients with active lupus nephritis showed that twice-daily 23.7 and 39.5 mg oral voclosporin plus standard of care (SOC) mycophenolate mofetil (MMF) and...
11:39 , Dec 1, 2016 |  BC Week In Review  |  Clinical News

Xiaflex: Ph IIa data

A double-blind, U.S. and Australian Phase IIa trial in 75 patients with Dupuytren’s disease and ≥1 palmar nodule showed that a single injection of Xiaflex significantly reduced mean nodule surface area, consistency score and hardness...
00:55 , Nov 8, 2016 |  BC Extra  |  Company News

Management tracks

Cancer company Neon Therapeutics Inc. (Cambridge, Mass.) named Richard Gaynor president of R&D. He was SVP of global product development and medical affairs in the oncology division at Eli Lilly and Co. (NYSE:LLY). Rare disease...
23:46 , Nov 4, 2016 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 12 biotechs and pharmas are expected to report earnings this week. (A) Nine-month EPS; (B) Fiscal 2Q; (C) First half EPS Company Date Pre/post mkt 3Q16 EPS est 3Q15 EPS...
07:00 , Oct 31, 2016 |  BioCentury  |  Politics, Policy & Law

Funding conundrum

  Rivers of pharmaceutical industry cash are keeping U.S. patient groups afloat, but in the absence of widely adopted transparency and governance principles, the funding flows could erode the perceived integrity, independence and reputations of...
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

Better together

Sinking valuations for specialty pharmas comparable to the Essential Health business of Pfizer Inc. (NYSE:PFE) and a resurgent stock price led Pfizer to conclude it was better off keeping its innovative and established products businesses...
07:00 , Sep 23, 2016 |  BC Extra  |  Company News

Management tracks

Zambon Co. S.p.A. (Milan, Italy), which develops CNS, respiratory and pain therapies, named Roberto Tascione CEO. He was president and CEO for Italy at Bristol-Myers Squibb Co. (NYSE:BMY). Generics company Endo International plc (NASDAQ:ENDP; TSX:ENL)...